Lawrence, Andrew David ![]() |
Abstract
The primary pathology in Alzheimer's disease (DAT) occurs in the basal forebrain cholinergic system (BFCS), which provides the major cholinergic innervation to the neocortex, hippocampus and amygdala. Consistent with the 'cholinergic hypothesis' of dementia in DAT, the most effective treatments so far developed for DAT are drugs which act to boost the functions of the BFCS. These include the centrally acting cholinesterase inhibitor tacrine, and the cholinergic agonist nicotine, acute administration of which leads to an improvement in attentional functions, in line with recent animal studies of the role of the BFCS in cognition. We conclude that future research should include the development of more potent, longer-lasting, less toxic cholinergic agents, which appear to be the best candidates for alleviating the cognitive symptomatology of DAT. Such drugs may also be useful in the treatment of a number of other cognitive disorders, including Lewy body dementia, attention deficit/hyperactivity disorder, and schizophrenia.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Psychology Neuroscience and Mental Health Research Institute (NMHRI) |
Subjects: | B Philosophy. Psychology. Religion > BF Psychology R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry R Medicine > RM Therapeutics. Pharmacology |
Uncontrolled Keywords: | Alzheimer's disease - cholinergic - attention - memory - psychopharmacology |
Publisher: | Springer Verlag |
ISSN: | 0364-3190 |
Last Modified: | 21 Oct 2022 09:10 |
URI: | https://orca.cardiff.ac.uk/id/eprint/35497 |
Citation Data
Cited 105 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |